EVALUATION OF CARDIOVASCULAR RISK FACTORS AND PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH DIAGNOSIS OF ANKYLOSING SPONDYLITIS:

Severino Correia Do Prado Neto1, Érika Carvalho de Aquino2, Jozélia Rêgo1, Nilzio Da Silva1, Fabiana Pina1. 1Hospital das Clinicas de Goiânia – Universidade Federal de Goiás, Goiânia, Brazil; 2Universidade Federal de Goiás, Goiânia, Brazil

Background: Cardiovascular events are the main causes of mortality in patients with Ankylosing Spondylitis. In addition, a higher prevalence of Metabolic Syndrome is reported in this group. With immunobiological therapy, much progress has been made in controlling the inflammatory process, but the cardiovascular risk remains high.

Objectives: To evaluate the prevalence of cardiovascular risk factors and Metabolic Syndrome in patients with Ankylosing Spondylitis at the Rheumatology Outpatient Clinic of HC-UFG and to correlate them with epidemiological, clinical, laboratory and radiographic characteristics of the disease.

Methods: Data from 59 patients were collected in medical records between July and August 2018. Clinical characteristics, cardiovascular risk factors and metabolic components were analyzed. Descriptive analyzes of the data were made, prevalences and their reasons were calculated. The associations between variables were assessed by chi-square test and Fisher’s exact test.

Results: 81.4% were male, 67.8% self-denominated non-whites, average age 46.7 years. Isolated axial joint involvement was the most common. Clinical, laboratory and radiographic characteristics of the disease. The prevalence of Metabolic Syndrome was below that is poorly understood. It has been suggested that the initial presentations may predict poor mortality.

Conclusion: The prevalence of Metabolic Syndrome was below that is poorly understood. It has been suggested that the initial presentations may predict poor mortality.

REFERENCES

Disclosure of Interests: None declared

PREVENTION OF VENOUS THROMBOEMBOLISM AND THE RISK OF POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER TOTAL HIP ARTHROPLASTY:

Alenur Rubnikov1, Evgueni Bialik2, Tatiana Reshetnyak2, Sergey Makarov2, Alexander Khrasov2, Sergey Maglevayev2, Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 2Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: According to the administrative data, confirmed by several meta-analyses, patients with rheumatoid arthritis (RA) in comparison with the general population shows an increased risk of venous thromboembolic complications more than twice. Drug prevention can reduce the risk of venous thromboembolism (VTE) in patients with rheumatic diseases.

Objectives: The aim of this study was to analyze frequency of VTE, risk of bleeding and complications of the postoperative wound in patients with RA and osteoarthritis (OA) after total hip arthroplasty (THA).

Methods: Study included 486 patients (212 - with RA and 274 - with OA) who underwent primary THA. Each group of patients was divided into 5 subgroups by type of drug therapy (1-nadroparin calcium; 2-dabigatran etexilate; 3-nadroparin calcium with transfer to dabigatran etexilate). Intraperioperative blood loss and the wound healing process were assessed during the first 7 days after surgery.

Results: Postoperative VTE were reported in 36 (7.4%) of 486 patients. VTE in patients with RA were detected significantly less frequently than in OA (1.2% and 6.1%, p = 0.0013). Bleeding that required transfusion by serum Immunoglobulins levels (2), while symptoms such as fatigue remaining stable over time (3).

References:


Disclosure of Interests: None declared

REFERENCES


DISEASE EVOLUTION OF PRIMARY SJÖGRÉN’S SYNDROME – A LONGITUDINAL STUDY

Inês Reis de Figueiredo1, Jessica Tam2, Dennis Lendrem2, Josephine Vila3, Elizabeth Kidd4; Julie Norris5, Ben Hargreaves6, Wong Fan Ng7,1. 1Unidade de Doenças Auto-imunes/Medicina 7,2 Hospital de Curty Cabral, Centro Hospitalar Universitário Lisboa Central (CHULC). Lisboa, Portugal; 2Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle- Upon-Tyne, United Kingdom; 3Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

Background: The natural history of primary Sjögren’s syndrome (pSS) remains poorly understood. It has been suggested that the initial presentations may predict the course of disease (1), with gradual reduction of biological activity as measured by serum Immunoglobulins levels (2), while symptoms such as fatigue remaining stable over time (3).

Objectives: To evaluate how pSS progresses over time using ESSDAI (Eular Sjögren’s Syndrome Disease Activity Index) and the ESSPRI (Eular Sjögren’s Syndrome Patient Index), EQSD-Time trade off (TTO) and Visual Analogue Scale (VAS) of health states.

Methods: Routine clinical data from a large single centre cohort in the UK were analysed on patients with >3 clinical visits, including up to the 10th visit. Outcomes (ESSDAI/ESSPRI and their component scores, EQSD-3L and VAS) were analyzed by a random effects linear regression using STATA 14.

Results: 346 patients out of 858 included, with a female preponderance of 89%, and median age of 63 years. The median follow up time was 4.9 years, and median disease duration of 12 years. Anti-Ro was positive in 61% and anti-La in 42% of the patients.

ESSDAI score decreased 0.1 point per visit (p=0.006). Anti-Ro and anti-La positive patients exhibiting a lower score (p=0.012 and 0.031), and patients with MAL at presentation ad a score up to 6 points higher (p=0.002). Regarding the ESSDAI domains, the constitutional and haematological domains showed increased activity (P-value<0.0001 and 0.018), with Anti-Ro and/or Anti-La patients having higher scores (p<0.0001 and 0.001). In contrast, the glandular, articular and peripheral nervous system domains showed decreases over time (P-values 0.003, 0.006 and <0.0001).

ESSPRI score increased 0.05 point/visit (P=0.0001). While Dryness scores remained relatively constant, Pain and Fatigue components of the ESSPRI increased over time (both p<0.0001). Dryness scores were higher in female patients (p=0.04). EQSD-TTO worsened by 0.03 point/visit (p<0.0001), but the VAS health states remained stable.

Conclusion: Our data suggest that symptoms of fatigue and pain as well as health utility worsen over time, whereas different ESSDAI domains showed different trends over time. Longer term follow-up to further understand the natural history of pSS is warranted.

REFERENCES


Disclosure of Interests: None declared
of blood in RA were found significantly more often than in OA (respectively 14.4% and 5.7% of cases; χ²(1) = 0.001). The number of cases requiring cancellation of anti-coagulant therapy in patients with RA was significantly higher compared with the OA group (6.4% and 1.4%, respectively). Slow wound healing in RA was more common (n = 56; 26.4%) than in OA (n = 14; 5.1%). In patients who underwent monotherapy with calcium nadroparin VTE occurred more often than when using combination therapy (χ²(1) = 0.001) and more often than in the group of dabigatran etexilate (p > 0.05).

Conclusion: The frequency of VTE, the risk of bleeding and complications of postoperative wound in patients with RA and OA after THA were analyzed. So, our study determined the dependence of VTE complications and bleeding risk according to the patient's underlying nosology. Also the advantage of combined postoperative therapy over others was evaluated.

Disclosure of Interests: None declared


TESTING DIFFERENT ITEMS INCLUDED IN THE DEFINITION OF REMISSION IN A MULTICENTRE SLE COHORT

Francesca Saccon1, Margherita Zen1, Maitre Gatto1, Domenico Pe Margiotta2, Fulvia Ceccarelli3, Giulia Frontini4, Gabriella Moroni4, Alessandra Bortoluzzi5, Marcello Govoni5, Viola Signorini6, Marta Mosca6, Francesca Dall’ara1, Angela Tincani1, Anna Chiara Frigo8, Antonella Afeltra2, Fabrizio Conti3, Andrea Doria1, University of Brescia, Rheumatology and Clinical Immunology Unit Spedali Civili and Dep. of Clinical and Experimental Science, Brescia, Italy; University of Padova, Department of Internal Medicine, Padova, Italy; University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Dep. of Medical Sciences, Ferrara, Italy; University of Pisa, Rheumatology Unit, Dep. of Internal Medicine, Pisa, Italy; University of Brescia, Rheumatology and Clinical Immunology Unit Spedali Civili and Dep. of Clinical and Experimental Science, Brescia, Italy; University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Dep. of Medical Sciences, Ferrara, Italy; University of Pisa, Rheumatology Unit, Dep. of Internal Medicine, Pisa, Italy; University of Brescia, Rheumatology and Clinical Immunology Unit Spedali Civili and Dep. of Clinical and Experimental Science, Brescia, Italy; University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Dep. of Medical Sciences, Ferrara, Italy; University of Pisa, Rheumatology Unit, Dep. of Internal Medicine, Pisa, Italy.

Background: Remission is the most desirable target in the treatment systemic lupus erythematosus (SLE) however, a universally accepted definition of remission in SLE is still missing.

Objectives: To test the contribution of the different items included into the currently used definitions of remission in SLE.

Methods: We studied 646 Caucasian patients from a multicentre lupus cohort followed for at least 5 years: female 585 (90.6%), mean age at baseline 40.59±12.14 years, mean disease duration 9.18±6.86 years. Disease activity was assessed by clinical SLE Disease Activity Index 2000 (cSLEDAI) and SELENA-SLEDAI physician global assessment (PGA), and damage by Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI). To test the performance of the different items included in the definitions of SLE remission [1, 2] we identify 7 subtypes of remission: (1) PGA (0-3); (2) cSLEDAI=0; (3) prednisone (PDN)=5mg/day; (4) PGA=0.5 and PDN=5mg/day; (5) cSLEDAI=0 and PGA=0.5; (6) cSLEDAI=0 and PDN=5mg/day; (7) cSLEDAI=0 and PDN=5mg/day and PGA=0.5. The effect of remission on SDI was evaluated by Poisson regression analysis.

Results: The number of patients achieving remission according to the different definitions is shown in Figure 1. The proportion of patients who maintained prolonged remission (5-consecutive years) was: PGA=0.5 13.0%; cSLEDAI=0 18.4%; PDN=5mg/day 34.4%; PGA=0.5 and PDN=5mg/day 12.5%; cSLEDAI=0 and PGA=0.5 12.7%; cSLEDAI=0 and PDN=5mg/day 16.6%; cSLEDAI=0 and PDN=5mg/day and PGA=0.5 12.4%.

When PGA=0.5 was added to cSLEDAI, 198 (30.7%) patients lost 353 years in remission (1.8 years/patient); among them 195 (98.5%) showed a 0.5PGA=1 suggesting a low disease activity state (LDA). When PGA=0.5 was added to cSLEDAI=0 and PDN ≤5mg/day, 151 (23.5%) patients lost 254 years in remission (1.7 years/patient); among them 149 (98.0%) showed a 0.5PGA=1 suggesting again LDA. All remission subtypes were protective against damage (p < 0.001), however cSLEDAI=0 showed the best performance (lower AIC) (Table 1). At multivariate analysis all remission subtypes lasting ≥2 consecutive years were protective against damage (p < 0.001), except PDN≤5mg/day which was protective after 4 years.

Conclusion: The prevalence and extent of damage significantly decreased as the time spent in remission increased, irrespective of the remission subtype. The addition of PGA=0.5 to cSLEDAI=0 or to cSLEDAI=0 and PDN≤5mg/day results in a decrease in the time spent in remission without significant difference in damage accrual.

REFERENCES

Disclosure of Interests: Francesca Saccon: None declared, Margherita Zen: None declared, Maitre Gatto: None declared, Domenico Pe Margiotta: None declared, Fulvia Ceccarelli: None declared, Giulia Frontini: None declared, Gabriella Moroni: None declared, Alessandra Bortoluzzi: None declared, Marcello Govoni: None declared, Viola Signorini: None declared, Marta Mosca: None declared, Francesca Dall’ara: None declared, Angela Tincani: None declared, Anna Chiara Frigo: None declared, Antonella Afeltra: None declared, Fabrizio Conti: None declared, Andrea Doria: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, AlphaSigma, Lilly, Janssen, Cellgenic, Novartis, Anna Chiara Frigo: None declared, Antonella Afeltra Grant/research support from: MSD, PFIZER, ABBVIE, ROCHE, UCB, Speakers bureau: MSD, PFIZER, BMS, ROCHE, SANOFI, fabrizio conti: None declared, Andrea Doria: None declared.


Figure 1

TESTING DIFFERENT ITEMS INCLUDED IN THE DEFINITION OF REMISSION IN A MULTICENTRE SLE COHORT

Table 1. Performance of 7 different remission subtypes in defining the risk of damage accrual (upper part) and the goodness-of-fit of the model (lower part).

<table>
<thead>
<tr>
<th>Remission Subtype</th>
<th>AIC</th>
<th>BIC</th>
<th>Age</th>
<th>Gender</th>
<th>BMI</th>
<th>Stage</th>
<th>Estrogen Receptor Status</th>
<th>Rate of Damage Accrual</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGA=0.5</td>
<td>123.4</td>
<td>135.6</td>
<td>0.5</td>
<td>Male</td>
<td>25</td>
<td>Positive</td>
<td>12.3%</td>
<td>0.5</td>
</tr>
<tr>
<td>cSLEDAI=0</td>
<td>112.3</td>
<td>124.5</td>
<td>0.5</td>
<td>Female</td>
<td>30</td>
<td>Positive</td>
<td>18.4%</td>
<td>0.5</td>
</tr>
<tr>
<td>PDN≤5mg/day</td>
<td>103.2</td>
<td>115.4</td>
<td>0.5</td>
<td>Male</td>
<td>25</td>
<td>Positive</td>
<td>9.8%</td>
<td>0.5</td>
</tr>
<tr>
<td>cSLEDAI=0 and PGA=0.5</td>
<td>101.2</td>
<td>113.4</td>
<td>0.5</td>
<td>Female</td>
<td>30</td>
<td>Positive</td>
<td>16.7%</td>
<td>0.5</td>
</tr>
<tr>
<td>cSLEDAI=0 and PDN≤5mg/day</td>
<td>100.1</td>
<td>112.3</td>
<td>0.5</td>
<td>Male</td>
<td>25</td>
<td>Positive</td>
<td>13.2%</td>
<td>0.5</td>
</tr>
<tr>
<td>cSLEDAI=0 and PDN≤5mg/day and PGA=0.5</td>
<td>99.0</td>
<td>111.2</td>
<td>0.5</td>
<td>Female</td>
<td>30</td>
<td>Positive</td>
<td>10.8%</td>
<td>0.5</td>
</tr>
</tbody>
</table>

VITAMIN D AND PAIN SYNDROME IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT LETROZOLE

Stefania Sciacca, Nadia Melillo, Francesco Paolo Cantatore, University of Foggia – Medical Area Departments, Department of Medical and Surgical Science, Foggia, Italy

Background: The third-generation aromatase inhibitors (AIs) have shown a favorable overall risk–benefit profile in the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast cancer. Breast cancer patients treated with long term AIs experience arthralgias and musculoskeletal aching often described as bone pain, musculoskeletal disorder, arthralgia.

Objective: The purpose of this study was to investigate clinical, serological and anamnestic features associated to the joint pain syndrome in non-metastatic breast cancer patients treated with adjuvant AIs.

Methods: Between June 2017 and December 2017 patients with early stage estrogen receptor–positive breast carcinomas treated with adjuvant letrozole, attending our Rheumatologic clinic to undergo osteoporosis screening; were included Pre-existing symptoms and clinical, serological and imaging features were evaluated to assess the type of musculoskeletal disorder.

Figure 1

Figure 1. Number of patients in remission according to the 3 single items: prednisone ≤5mg/day, PGA=0.5 (cSLEDAI=0), and their overlap during a follow-up period of 5 years for all patients. A) Patients achieving at least 1 year remission. B) Patients achieving prolonged remission (5-consecutive years).

Figure 1. Number of patients in remission according to the 3 single items: prednisone ≤5mg/day, PGA=0.5 (cSLEDAI=0), and their overlap during a follow-up period of 5 years for all patients. A) Patients achieving at least 1 year remission. B) Patients achieving prolonged remission (5-consecutive years).

Figure 1. Number of patients in remission according to the 3 single items: prednisone ≤5mg/day, PGA=0.5 (cSLEDAI=0), and their overlap during a follow-up period of 5 years for all patients. A) Patients achieving at least 1 year remission. B) Patients achieving prolonged remission (5-consecutive years).